|
|
Post by mytakeonit on Apr 5, 2023 14:01:18 GMT -5
All of ye with little faith ... as I said a long time ago ... The purchase of V-Go was done to acquire a huge sales team and and an established clientele that was at minimal cost. Most of that sales team was eventually let go ... and we ended up not having to do all the footwork to get these new clients. V-Go has essentially paid for itself. Now do you remember?  But, that's mytakeonit |
|
|
|
Post by prcgorman2 on Apr 5, 2023 15:11:15 GMT -5
Good point. Buying clients (and subscribers) is generally cheaper than trying to acquire new ones with prospecting. awesomo seems very concerned he needs to know precisely whether V-Go is or will be profitable. Mango generously volunteered to do some info-mining to help awesomo. I wish Mango luck. awesomo not so much.
|
|
|
|
Post by awesomo on Apr 5, 2023 15:47:25 GMT -5
Good point. Buying clients (and subscribers) is generally cheaper than trying to acquire new ones with prospecting. awesomo seems very concerned he needs to know precisely whether V-Go is or will be profitable. Mango generously volunteered to do some info-mining to help awesomo. I wish Mango luck. awesomo not so much. I can taste the salt from here. I suggest learning to breathe... |
|
|
|
Post by mango on Apr 5, 2023 15:55:32 GMT -5
All of ye with little faith ... as I said a long time ago ... The purchase of V-Go was done to acquire a huge sales team and and an established clientele that was at minimal cost. Most of that sales team was eventually let go ... and we ended up not having to do all the footwork to get these new clients. V-Go has essentially paid for itself. Now do you remember? But, that's mytakeonit The Accountant has spoken. Mahalo |
|
|
|
Post by sayhey24 on Apr 6, 2023 15:44:05 GMT -5
SG&A expenses aren't broken up by product, so it is a portion of the increase. The point is, even if you disregard all other expenses, just the gross profit from V-Go sales won't cover the $10M in one year that mango and others claimed would happen and lead to "profitability within one year". Still waiting for his profit analysis by the way... I’m not certain that I ever said it *will* pay for itself within the first year, I believe I said it *may* or *could*. I may be wrong, however, and you’re welcome to find the post and paste it here for us to see. Anyways, I emailed MannKind asking for the operating/related costs pertaining to VGo for 2022 so we can determine exactly how much it brought in profit for 2022, which will give us a better idea as to what the total profit the 12 months ending post acquisition of VGo. Mango - I can tell you V-Go brought in ZERO profit for 2022. As Mike said afrezza thanks to Tyvaso DPI cover a lot of the factory costs is now break even, The Board gave Mike until end of year 2023 to make V-Go break even. We will see. If Mike can make that happen all the better and with 2M shares I am sure Mike wants the pps to go to $100. If he can't make it break even then he needz to man up and make some decisions. My old boss was a pretty ruthless guy but GE was very profitable when he was steering the ship. I can't see Mike finding a buyer, and if its not profitable he did not fix it so that leaves closes. My old friend Bob Loungio was the Comptroller of RCA when Jack bought the place. We sold parts of it off for more than we paid for the entire company. Bob hated Welch, his style and the fact he destroyed RCA. However, he could not argue the numbers. |
|
|
|
Post by sportsrancho on Apr 6, 2023 17:50:15 GMT -5
“The Board gave Mike until end of year 2023 to make V-Go break even. We will see.”
Somehow I missed that memo?
Did he say that on the call and I just missed it?
|
|
|
|
Post by caesar on Apr 6, 2023 18:25:45 GMT -5
“The Board gave Mike until end of year 2023 to make V-Go break even. We will see.” Somehow I missed that memo? For what it's worth, Mike said a number of times that the board mandated that Afrezza/V-Go (Diabetic/Insulin) must be generating positive cash flow by the end of the year. V-Go was brought on board so that the reps have multiple products for managing diabetes in their bag (so to speak). The reps prior to the purchase of V-Go had to go it alone - with V-Go, at least able to get in the door. With any kind of luck, both these products will make in roads, if not then it's time for the company to offload both of these non-performing drugs. I am not a fortune teller, and if I was, I would have never bought into Al Manns obsessive need to disrupt the insulin marketplace. I did my due diligence prior to investing in Technosphere, without giving a second thought to the viability of Afrezza. Al Mann convinced me that they had dotted all the "i's" and cross all the "t's" when it came to dosing. He played me and the balance of the large investors like a broken fiddle. Neither Al or the clinicians at Mannkind had a clue on how to dose Afrezza and here we are a decade later with sh*t to show for that oversight. Proof of concept and a manufacturing plant without industry buy-in is a recipe for failure. I am ready to move on with the pipeline to finally utilize Technosphere for what it was intended for, treating illnesses that cannot be adequately treated by pills or needles. Maybe Vdex (Bill) can make a go of it after Mannkind sell the marketing rights to him/them at the end of this year - that would be poetic justice! |
|
|
|
Post by prcgorman2 on Apr 6, 2023 20:38:06 GMT -5
Al Mann has been dead for 8 years. He isn’t paying all the people who keep posting messages and videos about their “life changing” experiences treating their diabetes with Afrezza in their toolkit. I don’t think I would still own any MNKD if I felt as contemptible about the company and it’s dead founder as you apparently do. That’s burdensome. Best of luck.
|
|
|
|
Post by mango on Apr 6, 2023 21:22:56 GMT -5
“The Board gave Mike until end of year 2023 to make V-Go break even. We will see.” Somehow I missed that memo? For what it's worth, Mike said a number of times that the board mandated that Afrezza/V-Go (Diabetic/Insulin) must be generating positive cash flow by the end of the year. V-Go was brought on board so that the reps have multiple products for managing diabetes in their bag (so to speak). The reps prior to the purchase of V-Go had to go it alone - with V-Go, at least able to get in the door. With any kind of luck, both these products will make in roads, if not then it's time for the company to offload both of these non-performing drugs. I am not a fortune teller, and if I was, I would have never bought into Al Manns obsessive need to disrupt the insulin marketplace. I did my due diligence prior to investing in Technosphere, without giving a second thought to the viability of Afrezza. Al Mann convinced me that they had dotted all the "i's" and cross all the "t's" when it came to dosing. He played me and the balance of the large investors like a broken fiddle. Neither Al or the clinicians at Mannkind had a clue on how to dose Afrezza and here we are a decade later with sh*t to show for that oversight. Proof of concept and a manufacturing plant without industry buy-in is a recipe for failure. I am ready to move on with the pipeline to finally utilize Technosphere for what it was intended for, treating illnesses that cannot be adequately treated by pills or needles. Maybe Vdex (Bill) can make a go of it after Mannkind sell the marketing rights to him/them at the end of this year - that would be poetic justice! Will you post the link to where that was said, ever? I think what you are confused about is when Mike said “We believe this business will be breakeven by the end of the year and that’s our number one mandate.” from the recent Latham Partners call. I have yet to find anything remotely close in any transcript or call where the Board mandated anything. Just like when people misheard Mike say “invest in growth” and thought he said rest and grow. I believe the same misinterpretation happened with this. Feel free to prove me wrong (with a source). Source where Mike says the above that I quote: wsw.com/webcast/lytham7/mnkd/2030460 |
|
|
|
Post by hellodolly on Apr 7, 2023 5:00:06 GMT -5
For what it's worth, Mike said a number of times that the board mandated that Afrezza/V-Go (Diabetic/Insulin) must be generating positive cash flow by the end of the year. V-Go was brought on board so that the reps have multiple products for managing diabetes in their bag (so to speak). The reps prior to the purchase of V-Go had to go it alone - with V-Go, at least able to get in the door. With any kind of luck, both these products will make in roads, if not then it's time for the company to offload both of these non-performing drugs. I am not a fortune teller, and if I was, I would have never bought into Al Manns obsessive need to disrupt the insulin marketplace. I did my due diligence prior to investing in Technosphere, without giving a second thought to the viability of Afrezza. Al Mann convinced me that they had dotted all the "i's" and cross all the "t's" when it came to dosing. He played me and the balance of the large investors like a broken fiddle. Neither Al or the clinicians at Mannkind had a clue on how to dose Afrezza and here we are a decade later with sh*t to show for that oversight. Proof of concept and a manufacturing plant without industry buy-in is a recipe for failure. I am ready to move on with the pipeline to finally utilize Technosphere for what it was intended for, treating illnesses that cannot be adequately treated by pills or needles. Maybe Vdex (Bill) can make a go of it after Mannkind sell the marketing rights to him/them at the end of this year - that would be poetic justice! Will you post the link to where that was said, ever? I think what you are confused about is when Mike said “We believe this business will be breakeven by the end of the year and that’s our number one mandate.” from the recent Latham Partners call. I have yet to find anything remotely close in any transcript or call where the Board mandated anything. Just like when people misheard Mike say “invest in growth” and thought he said rest and grow. I believe the same misinterpretation happened with this. Feel free to prove me wrong (with a source). Source where Mike says the above that I quote: wsw.com/webcast/lytham7/mnkd/2030460Correct, I remember it as MNKD becoming cash flow break even. Nothing about V-Go, Afrezza, though some will argue with the exception of Tyvaso...Afrezza and V-Go is MNKD. |
|
|
|
Post by Clement on Apr 7, 2023 7:41:42 GMT -5
wsw.com/webcast/svb8/mnkd/1613790February 15, 2023 1:40 p.m. ET SVB Securities Global Biopharma Conference MC said at 27:16 in the video: "... we have kinda taken the board's feedback and kinda mandated that the diabetes business is gonna track to CFBE by the end of this year."
|
|
|
|
Post by mango on Apr 7, 2023 8:39:11 GMT -5
wsw.com/webcast/svb8/mnkd/1613790February 15, 2023 1:40 p.m. ET SVB Securities Global Biopharma Conference MC said: "... we have kinda taken the board's feedback and kinda mandated that the diabetes business is gonna track to CFBE by the end of this year." Doesn’t sound anything like what some people have been saying. Based on the two times Mike has mentioned the word mandate that I’m aware of, it appears the Board is wanting CFBE of the diabetes business by end of year and making that a number 1 priority. It does not imply MannKind will be selling off the diabetes business if they fail to reach that goal, and I highly doubt that would ever happen, especially with Peds approval coming next year, India approval, and this new large scale Pump Switch trial. If you listen to Mike in the recent calls he gives absolutely no indication selling off Afrezza, but regardless, it appears they are confident of CFBE by end of year and are “mandating” that happen. I personally believe people have taken what he has said out of context. “Kinda mandate” and “that’s our number one mandate” does not equate to selling off the business if not successful. |
|
|
|
Post by mango on Apr 7, 2023 8:50:15 GMT -5
“MannKind has not disclosed any operating costs differentiated by brand; we have only reported costs on the EBU level.”
From IR on VGo operating costs.
|
|
|
|
Post by cretin11 on Apr 7, 2023 8:50:32 GMT -5
Agree it doesn’t equate to a promise to sell off the division if not CFBE, nor would it be wise to show that card even if it were the case. “Kinda taken the board’s feedback and kinda mandated” kinda gives plenty of wiggle room to be interpreted different ways. Plus, even if the plan is to sell off the division, that can’t be done without a buyer.
|
|
|
|
Post by prcgorman2 on Apr 7, 2023 10:30:32 GMT -5
Agree it doesn’t equate to a promise to sell off the division if not CFBE, nor would it be wise to show that card even if it were the case. “Kinda taken the board’s feedback and kinda mandated” kinda gives plenty of wiggle room to be interpreted different ways. Plus, even if the plan is to sell off the division, that can’t be done without a buyer. Agree, and discussing a sale or a buyer is not interesting because of how unlikely it is (at this time). It’s also worth noting that the next comment Mike made with regard to CFBE for the “endocrine” unit was that “Afrezza is already CFBE”. I’m not angry or upset about V-Go, but I do agree with sayhey24 (and awesomo) that it needs to be able to pay for itself, or be discontinued. Afrezza, unfortunately, also cannot be a charity, but I know I would be willing to be operating at a small loss for a few more years, but according to Mike’s comment, that’s not even a concern. |
|
